Celgene: European Decision Not Best Case Scenario, Not Worst Case Either

Celgene (CELG) today announced that a European regulatory committee had issued a positive opinion on its cancer drug Revlimid. Bernstein’s Geoffrey Porges and Wen Shi explain the significance: Boston Globe via Getty Images This morning, the European Committee for Medicinal Products (CHMP) announced a positive opinion recommending the expansion of the Revlimid EU label to [...]